Nipple Fissure Repair Efficacy Evaluation Test: Methods, Indicators, and Applications

The Nipple Fissure Repair Efficacy Evaluation Test is a clinical and instrumental assessment program designed to verify the healing performance of nipple care products used during lactation. By quantifying indicators such as crack closure rate, transepidermal water loss, skin hydration, erythema reduction, and pain relief, the test provides scientific evidence to substantiate repair efficacy claims. This article outlines the testing samples, evaluation items, methodologies, and typical applications of the test for manufacturers and brands.

Technical Overview

Nipple fissure, also known as nipple crack or rhagade, is one of the most frequently reported complications during breastfeeding. It is typically caused by mechanical friction from infant latching, prolonged moisture exposure, and disruption of the skin barrier. Symptoms range from superficial dryness and flaking to deep cracks, erosion, bleeding, and severe pain, which may lead to early weaning if not properly managed. Nipple repair creams, lanolin balms, and hydrogel patches are widely used to accelerate healing and relieve discomfort.

The Nipple Fissure Repair Efficacy Evaluation Test is a structured assessment program that combines clinical visual grading, bioengineering instrumental measurements, and subjective scoring to substantiate the repair efficacy of such products. Testing is typically performed by accredited third-party laboratories or clinical research institutions under the ethical principles of the Declaration of Helsinki, in line with cosmetic claim substantiation frameworks such as EU Regulation (EC) No 1223/2009 and Commission Regulation (EU) No 655/2013, as well as efficacy claim evaluation requirements for cosmetics in China.

Core objectives of the evaluation include:

• Quantifying the rate of crack closure and recovery of skin integrity
• Measuring restoration of skin barrier function and hydration levels
• Assessing reduction of inflammation and erythema
• Documenting pain relief and improved breastfeeding comfort
• Confirming cutaneous tolerability and safety during lactation

Testing Samples

Cosmetic Nipple Care Products

Creams, balms, and ointments marketed for nursing mothers, including purified lanolin products and vegetable-oil-based formulations containing ingredients such as squalane, shea butter, ceramides, panthenol, and allantoin. Samples should be submitted in final market packaging from a defined production batch, typically with multiple batches for consistency verification.

Hydrogel Patches and Wound Dressings

Polymer hydrogel pads and moist wound-healing dressings classified as medical devices. In addition to repair efficacy, these products are evaluated against physical performance requirements such as moisture vapor transmission and conformability, referencing frameworks including EN 13726, ASTM F2900 for hydrogel characterization, and biocompatibility evaluation under the ISO 10993 series.

Prototype and Reformulated Products

Development-stage formulations submitted for comparative screening, including prototype textures, alternative preservative systems, or upgraded active ingredient concentrations, used to support formulation optimization decisions prior to market launch.

Reference and Control Materials

Untreated control areas, vehicle bases without active ingredients, or marketed comparator products incorporated into controlled study designs to demonstrate superiority or non-inferiority of the test product.

Testing Items

The evaluation panel covers efficacy endpoints, instrumental indicators, and safety observations:

• Nipple damage severity grade based on standardized visual scoring scales covering erythema, cracking, erosion, and crusting
• Healing rate and effective cure rate at defined time points, such as Day 3, Day 7, and Day 14
• Transepidermal water loss (TEWL) as an indicator of barrier recovery
• Stratum corneum hydration measured by capacitance or conductance methods
• Erythema index and skin color parameters determined by reflectance spectroscopy
• Surface roughness and crack morphology analyzed through 3D skin imaging
• Pain intensity on a visual analogue scale (VAS) and breastfeeding comfort questionnaires
• Skin tolerability, adverse events, and dermatological observations throughout the study
• Microbiological safety of the finished product where applicable, including preservative challenge testing under ISO 11930 and microbial enumeration under ISO 21149

Testing Methods

Clinical Study Design

Human efficacy trials recruit lactating women presenting with mild to moderate nipple fissures according to predefined inclusion and exclusion criteria. Studies follow a randomized, controlled, and where feasible blinded design, with the test product applied two to three times daily after feeding over a 7- to 14-day period. Assessments are scheduled at baseline and on Days 3, 7, and 14, with continuous safety monitoring. The protocol is reviewed and approved by an independent ethics committee before enrollment.

Dermatological Visual Grading

Trained dermatologists or lactation specialists grade lesion severity using standardized scales, documenting crack depth, erosion area, exudation, and crusting. Photographic documentation under controlled lighting and fixed camera parameters supports objective comparison between visits and independent retrospective review.

Bioengineering Instrumental Measurement

Barrier function is quantified with TEWL probes under standardized ambient conditions of approximately 20 to 22 degrees Celsius and 40 to 60 percent relative humidity, following internationally recognized bioinstrumentation guidance. Stratum corneum hydration is measured by capacitance-based corneometry, erythema by narrow-band reflectance spectroscopy, and lesion topography by 3D imaging systems that extract roughness parameters and erosion dimensions for healing-rate calculation.

Subjective Evaluation

Participants complete validated pain questionnaires, including a 100 mm visual analogue scale, and maintain diaries recording application compliance, breastfeeding duration, and comfort perception. These endpoints are particularly relevant because pain is the primary complaint driving product use among nursing mothers.

In Vitro Supporting Methods

Complementary laboratory models substantiate mechanisms of repair, including scratch-wound migration assays on human keratinocytes, reconstructed human epidermis wound-healing models, and quantification of barrier-related biomarkers such as filaggrin, involucrin, and inflammatory cytokines via immunoassays. These methods reduce reliance on human subjects during early development and support mechanistic claims.

Statistical Analysis

Within-group changes from baseline are analyzed using paired t-tests or Wilcoxon signed-rank tests depending on data distribution, while between-group comparisons apply ANOVA or non-parametric equivalents. Results are reported with 95 percent confidence intervals, and efficacy is concluded when predefined endpoints demonstrate statistically significant and clinically meaningful improvement.

Applications

Evaluation reports serve multiple purposes across the product lifecycle:

• Substantiation of repair, soothing, and moisturizing claims for regulatory filings and advertising compliance
• Support for efficacy dossiers required under cosmetic regulations in China, the EU, and other jurisdictions
• Comparative benchmarking against competitor or reference formulations during product development
• Scientific documentation for marketing materials, including clinically tested claims on packaging
• Quality consistency verification across production batches for post-launch surveillance
• Technical differentiation between cosmetic care products and medical device dressings in classification decisions

FAQ

How long does a complete evaluation take?

A standard clinical efficacy study, including recruitment, a 14-day in-use period, and final reporting, typically requires six to twelve weeks. Additional time should be reserved for ethics review and pilot feasibility assessments.

Is the test safe for breastfeeding mothers and infants?

Yes. Protocols are designed so that products are applied after feeding, and any residue is gently removed before the next feeding where required by product instructions. All ingredients are screened for suitability during lactation, and independent ethics committee approval with continuous adverse-event monitoring is mandatory.

What sample information should be provided?

Applicants should submit final packaged product from a defined batch, the full ingredient composition or INCI list, intended use instructions, and available stability and microbiological data, together with any prior safety assessments required to support the ethics application.

Can in vitro testing replace a clinical trial?

In vitro models such as reconstructed human epidermis wound-healing assays provide strong mechanistic support and screening data, but consumer-facing repair claims generally require human clinical evidence. Most regulatory frameworks expect human data for claims related to healing, soothing, and barrier repair.

Which product categories require this evaluation?

Any product claiming to repair cracked nipples, restore the nipple skin barrier, or relieve breastfeeding-related nipple damage should undergo this evaluation, including cosmetic creams and balms for nursing mothers as well as hydrogel dressings regulated as medical devices.